The trading price of CRISPR Therapeutics AG (NASDAQ:CRSP) closed lower on Monday, July 19, closing at $125.73, -0.41% lower than its previous close.
Traders who pay close attention to intraday price movement should know that it fluctuated between $122.0147 and $129.2198. In examining the 52-week price action we see that the stock hit a 52-week high of $220.20 and a 52-week low of $76.71. Over the past month, the stock has lost -1.21% in value.
CRISPR Therapeutics AG, whose market valuation is $9.59 billion at the time of this writing, is expected to release its quarterly earnings report Jul 26, 2021 – Jul 30, 2021. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by $3.52 per share this quarter, however they have predicted annual earnings per share of -$0.51 for 2021 and -$6.32 for 2022. It means analysts are expecting annual earnings per share growth of 90.40% this year and -1,139.20% next year.
The average estimate suggests sales will likely up by 2,223.00% this quarter compared to what was recorded in the comparable quarter last year. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2021 is $465.43 million. The company’s revenue is forecast to grow by 64,633.00% over what it did in 2021.
A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of CRISPR Therapeutics AG No upward and no downward comments were posted in the last 7 days. On the technical side, indicators suggest CRSP has a 50% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a Hold, while an average of long term indicators suggests that the stock is currently 50% Sell.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned CRSP a recommendation rating is 21. Out of them, 6 rate it a Hold, while 14 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged CRISPR Therapeutics AG (CRSP) as Underweight, while 1 advise Sell. Analysts have rated the stock Overweight, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
A quick review shows that CRSP’s price is currently -10.63% off the SMA20 and 0.40% off the SMA50. The RSI metric on the 14-day chart is currently showing 40.04, and weekly volatility stands at 4.93%. When measured over the past 30 days, the indicator reaches 5.63%. CRISPR Therapeutics AG (NASDAQ:CRSP)’s beta value is currently sitting at 2.27, while the Average True Range indicator is currently displaying 7.32. With analysts defining $117.00-$220.00 as the low and high price targets, we arrive at a consensus price target of $163.11 for the trailing 12-month period. The current price is about 6.94% off the estimated low and -74.98% off the forecast high, based on this estimate. Investors will be thrilled if CRSP’s share price rises to $165.00, which is the median consensus price. At that level, CRSP’s share price would be -31.23% below current price.
To see how CRISPR Therapeutics AG stock has been performing in comparison to its peers in the industry, here are the numbers: CRSP stock’s performance was -0.41% in the latest trading, and 36.15% in the past year, while Pieris Pharmaceuticals Inc. (PIRS) has traded 6.65% on the day and positioned 14.24% higher than it was a year ago. CRISPR Therapeutics AG has a P/E ratio of 0. Also in last trading session, the S&P 500 Index has plunged -1.59%, while the Dow Jones Industrial also saw a negative session, down -2.09% on the day.
An evaluation of the daily trading volume of CRISPR Therapeutics AG (NASDAQ:CRSP) indicates that the 3-month average is 1.44 million. However, this figure has increased over the past 10 days to an average of 1.02 million.
Currently, records show that 75.00 million of the company’s shares remain outstanding. The insiders hold 1.10% of outstanding shares, whereas institutions hold 58.40%. The stats also highlight that short interest as of Jun 14, 2021, stood at 3.36 million shares, resulting in a short ratio of 3.34 at that time. From this, we can conclude that short interest is 4.18% of the company’s total outstanding shares. It is noteworthy that short shares in June were down slightly from the previous month’s figure, which was 3.87 million. However, since the stock’s price has seen -17.88% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.